Proteomic classification of breast cancer

Dalia Kamel; Bernadette Brady; Adel Tabchy; Gordon B. Mills; Bryan Hennessy

doi:10.2174/138945012803530080

Proteomic classification of breast cancer

Dalia Kamel, Bernadette Brady, Adel Tabchy, Gordon B. Mills, Bryan Hennessy

Research output: Contribution to journal › Article

15 Scopus citations

Abstract

Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

Original language	English (US)
Pages (from-to)	1495-1509
Number of pages	15
Journal	Current Drug Targets
Volume	13
Issue number	12
DOIs	https://doi.org/10.2174/138945012803530080
State	Published - Dec 3 2012

Keywords

Breast cancer
Molecular technology
Proteome
RPPA

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.2174/138945012803530080

Fingerprint Dive into the research topics of 'Proteomic classification of breast cancer'. Together they form a unique fingerprint.

Cite this

Kamel, D., Brady, B., Tabchy, A., Mills, G. B., & Hennessy, B. (2012). Proteomic classification of breast cancer. Current Drug Targets, 13(12), 1495-1509. https://doi.org/10.2174/138945012803530080

@article{333820572e954b529d3cd460099314da,

title = "Proteomic classification of breast cancer",

abstract = "Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.",

keywords = "Breast cancer, Molecular technology, Proteome, RPPA",

author = "Dalia Kamel and Bernadette Brady and Adel Tabchy and Mills, {Gordon B.} and Bryan Hennessy",

year = "2012",

month = dec,

day = "3",

doi = "10.2174/138945012803530080",

language = "English (US)",

volume = "13",

pages = "1495--1509",

journal = "Current Drug Targets",

issn = "1389-4501",

publisher = "Bentham Science Publishers B.V.",

number = "12",

}

TY - JOUR

T1 - Proteomic classification of breast cancer

AU - Kamel, Dalia

AU - Brady, Bernadette

AU - Tabchy, Adel

AU - Mills, Gordon B.

AU - Hennessy, Bryan

PY - 2012/12/3

Y1 - 2012/12/3

N2 - Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

AB - Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

KW - Breast cancer

KW - Molecular technology

KW - Proteome

KW - RPPA

UR - http://www.scopus.com/inward/record.url?scp=84870183727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870183727&partnerID=8YFLogxK

U2 - 10.2174/138945012803530080

DO - 10.2174/138945012803530080

M3 - Article

C2 - 22974393

AN - SCOPUS:84870183727

VL - 13

SP - 1495

EP - 1509

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -